Eloralintide (natrium)

Eloralintide (LY 3841136) sodium is an AMYR agonist, which is promising for research of type 2 diabetes and obesity[1].

LY-3841136 (sodium)

12352209

Amylin Receptor

GPCR/G Protein

Metabolism-protein/nucleotide metabolism

Metabolic Disease

99.72

OC1=CC=C(C=C1)C[C@@H](C(N)=O)NC([C@H]([C@H](O)C)NC([C@H](CC(N)=O)NC([C@H](CO)NC(CNC([C@H](C(C)C)NC([C@H](CCC(O)=O)NC([C@H]([C@H](O)C)NC([C@H]2N(C([C@H]3N(C([C@H](CC(C)C)NC([C@H](CCCCNC(CC[C@@H](C(O)=O)NC(CC[C@@H](C(O)=O)NC(CCCCCCCCCCCCCCCCCCC(O)=O)=O)=O)=O)NC([C@H]4N(C(CNC([C@H](CC5=CC=CC=C5)NC([C@H](CC(N)=O)N(C([C@H](CC(N)=O)NC([C@H](CO)NC([C@H](CO)NC([C@H](CCCNC(N)=N)NC([C@H](C(C)C)NC([C@H](CC(C)C)NC([C@@](NC([C@H](CCC(O)=O)NC([C@H](C)NC([C@H](CC(C)C)NC([C@H](CCCN)NC(CNC([C@H]([C@H](O)C)NC([C@H](C)NC([C@H](CSCSC[C@@H]6NC(CC[C@@H](C(O)=O)N)=O)NC([C@H]([C@H](O)C)NC([C@H](C)NC([C@H]([C@H](O)C)NC([C@H](CC(N)=O)NC6=O)=O)=O)=O)=O)=O)=O)=O)=O)=O)=O)=O)=O)(CC7=CC=CC=C7)C)=O)=O)=O)=O)=O)=O)=O)C)=O)=O)=O)CCC4)=O)=O)=O)CCC3)=O)CCC2)=O)=O)=O)=O)=O)=O)=O)=O.[Na].[x]

C201H319N49O65S2.xNa

4526.10 (free base)

[1]A Phase 2, Parallel-Group, Double-Blind, Placebo-Controlled Study to Investigate Weight Management With LY3841136 and Tirzepatide, Alone or in Combination, in Adult Participants With Obesity or Overweight With Type 2 Diabetes.

Blue Ice

-80°C, 2 years; -20°C, 1 year (Powder, sealed storage, away from moisture)

http://file.medchemexpress.com/batch_PDF/HY-P10798A/Eloralintide-sodium-SDS-MedChemExpress.pdf

Peptides

Phase 2